Yearly Archives: 2019

This week we bring you another update from the European rheumatology conference held in Madrid (EULAR) which was attended by our pharmacist Carolyn Whiskin.  When a person carries excess weight, there is an increase in the production of inflammatory substances … Continue reading →

Today we bring you another update from the European Rheumatology Conference (EULAR). Certain types of infections can lead to arthritis, such as Lyme Disease and Chikungunya. Lyme disease, which is spread through deer ticks, has become more prevalent over the last several years, … Continue reading →

Our World Hepatitis Day event is coming up July 26th from 9am to 3pm at Gore Park in Hamilton. We will be be back testing people in the community for hepatitis C so that treatment can be offered to them. … Continue reading →

Another update from the recent European rheumatology conference (EULAR)… There are many inflammatory substances that can be produced in the body. TNF (tumour necrosis factor) and IL-6 (interleukin 6) are known to be high in Rheumatoid arthritis. Biologic Treatments for … Continue reading →

Today we bring you another update from the recent European Rheumatology Conference: EULAR that our Pharmacy Manager Carolyn Whiskin attended in June. Inflammation can have an impact on memory and emotional well-being. It is well known that when inflammation is high … Continue reading →

One of the risk factors for rheumatoid arthritis has been linked to periodontal disease. A study from Japan was presented at the recent European Rheumatology Conference (EULAR). It found that people who had rheumatoid arthritis along with periodontal disease had … Continue reading →

At the European rheumatology conference, known as EULAR, there were several sessions held simultaneously over the four day meeting. There were over 16,000 people in attendance. One of the sessions focused on safety. United States physician Dr. Kevin Winthrop outlined … Continue reading →

Our pharmacist Carolyn Whiskin is in Madrid this week attending the largest Rheumatology conference in the world (EULAR).  She will be reporting back on the newest findings reported at this meeting over the next several weeks. There will be over … Continue reading →

Skyrizi (risankizumab) is a new biologic for treating psoriasis. The first dose in Canada was injected at Charlton Health.  This treatment is given by injection as 2 prefilled syringes starting at week 0, week 4 and then every 12 weeks.  … Continue reading →

Approximately 14% of Canadians suffer from osteoarthritis. While there are currently 17 approved medications for preventing the progression of rheumatoid arthritis, there are none for OA. This is a multidimensional disease and in the past there has been resistance to … Continue reading →